Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GLAND PHARMA LTD.

NSE : GLANDBSE : 543245ISIN CODE : INE068V01023Industry : Pharmaceuticals & DrugsHouse : Private

BSE1919.3550.75 (+2.72 %)

PREV CLOSE ( ) 1868.60

OPEN PRICE ( ) 1849.25

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 3170

TODAY'S LOW / HIGH ( )1849.25 1929.00

52 WK LOW / HIGH ( )1200 2130

NSE1921.0042.9 (+2.28 %)

PREV CLOSE( ) 1878.10

OPEN PRICE ( ) 1878.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1921.00 (119)

VOLUME 431248

TODAY'S LOW / HIGH( ) 1871.50 1930.00

52 WK LOW / HIGH ( )1277.8 2131

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 20-03 1978

Management Info

Srinivas Sadu - Chairman - Managing Director

Registered Office

Address Survey No. 143-148, 150 & 151, Near Gandimaisamma ‘x’ Roads,D. P. Pally, Dundigal, Dundigal-gandimaisamma Mandal,Medchal- Malkajgiri District,
Hyderabad,
Telangana-500043

Phone 040 30510999

Email gland@glandpharma.com / investor@glandpharma.com

Website www.glandpharma.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

08Sep Gland Pharma informs about investor me
Pursuant to Regulation 30 read with Part A of the Securities and Exchang..

26Aug Gland Pharma receives USFDA’s approval
Gland Pharma has received approval from the United States Food and Drug..

12Aug Gland Pharma gets USFDA’s approval for
Gland Pharma has received approval from the United States Food and Drug..

12Aug Gland Pharma informs about press release
Pursuant to Regulation 30 read with Part A of Schedule III of the Securi..

12Aug Gland Pharma gets USFDA’s nod for Cang
Gland Pharma has received approval from the United States Food and Drug..

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	2692.58	10897.53
Gross Profit	3623.83	14655.85
Operating Profit	4135.86	16576.93
Net Sales	10388.35	41161.49

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Astrazeneca Pharma I (BSE) 9105.75 (0.80%)	M.Cap ( in Cr)22764.38
Glenmark Pharma (BSE) 2116.25 (3.10%)	M.Cap ( in Cr)59720.75
Dr. Reddy's Lab (BSE) 1293.45 (3.45%)	M.Cap ( in Cr)107952.28
Wockhardt (BSE) 1496.75 (2.54%)	M.Cap ( in Cr)24321.02
Acutaas Chemicals (BSE) 1504.50 (2.48%)	M.Cap ( in Cr)12317.18

Shareholding Pattern

	PROMOTERS	51.83%
	MUTUAL FUNDS/UTI	30.67%
	NON-INSTITUTION	7.93%
	FI/BANKS/INSURANCE	1.27%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	5.52
ICICI Pru MNC Fund(G)	3.67
ICICI Pru Pharma He...	3.57
Nippon India Pharma...	3.27
HDFC Pharma and Hea...	3.10
UTI Healthcare Fund...	3.00
UTI MNC Fund-Reg(IDCW)	2.72

Risk Disclosures on Derivatives

Smart Quotes

GLAND PHARMA LTD.